Kukje Pharma KRX:002720KOSPI
국제약품 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked2since Sep 11
In Q2 2026, Kukje Pharma reported revenue of ₩48.3bn, up 7.3% year on year, and operating profit of ₩2.1bn. Kukje Pharma (국제약품) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 22 with 1 article.
Filing signals Share pledge Screener
Kukje Pharma quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩48.3bn | +7.3% | ₩2.1bn margin 4.4% | ₩1.7bn |
| Q1 2026 | ₩44.0bn | +6.0% | ₩2.0bn margin 4.5% | ₩2.1bn |
| Q4 2025 derived | ₩43.3bn | +4.1% | −₩1.5bn margin −3.6% | −₩736m |
| Q3 2025 | ₩45.6bn | +15.1% | ₩1.9bn margin 4.2% | ₩1.9bn |
| Q2 2025 | ₩45.0bn | +19.6% | ₩3.5bn margin 7.8% | ₩2.7bn |
| Q1 2025 | ₩41.5bn | +10.6% | ₩2.3bn margin 5.5% | ₩1.9bn |
| Q4 2024 derived | ₩41.6bn | +18.0% | ₩943m margin 2.3% | ₩697m |
| Q3 2024 | ₩39.7bn | +23.4% | ₩1.7bn margin 4.2% | ₩1.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Kukje Pharma top stories 2 weeks, by number of outlets
- 1